Asprosin attenuates insulin signaling pathway through PKCδ-activated ER stress and inflammation in skeletal muscle
© 2019 Wiley Periodicals, Inc..
It has been reported that asprosin is a novel adipokine which is augmented in mice and humans with type 2 diabetes (T2DM). Asprosin stimulates hepatic gluconeogenesis under fasting conditions. However, the roles of asprosin in inflammation, endoplasmic reticulum (ER) stress, and insulin resistance in skeletal muscle has not been studied. In the currents study, elevated levels of asprosin expression were observed in adipocytes under hyperlipidemic conditions. Treatment of C2C12 myocytes with asprosin-induced ER stress markers (phosphorylated inositol-requiring enzyme 1 and eukaryotic initiation factor 2, and CHOP expression) as well as inflammation markers (interleukin-6 expression, phosphorylated IκB, and nuclear translocated nuclear factor-κβ). Finally, asprosin treatment promoted exacerbation of insulin sensitivity as determined by levels of insulin receptor substrate 1 and Akt phosphorylation as well as glucose uptake. Moreover, treatment of asprosin augmented protein kinase C-δ (PKCδ) phosphorylation and nuclear translocation, but suppressed messenger RNA expression of sarcoplasmic reticulum Ca2+ ATPase 2b in both C2C12 myocytes and in mouse soleus skeletal muscle. These asprosin-induced effects were markedly decreased in small interfering (si) RNA-mediated PKCδ-knockdown in C2C12 myocytes. These results suggest that asprosin results in impairment of insulin sensitivity in skeletal muscle through PKCδ-associated ER stress/inflammation pathways and may be a valuable strategy for management of insulin resistance and T2DM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:234 |
|---|---|
| Enthalten in: |
Journal of cellular physiology - 234(2019), 11 vom: 17. Nov., Seite 20888-20899 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jung, Tae Woo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.06.2020 Date Revised 27.08.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jcp.28694 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM296182249 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM296182249 | ||
| 003 | DE-627 | ||
| 005 | 20231225085302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jcp.28694 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0987.xml |
| 035 | |a (DE-627)NLM296182249 | ||
| 035 | |a (NLM)30997682 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jung, Tae Woo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Asprosin attenuates insulin signaling pathway through PKCδ-activated ER stress and inflammation in skeletal muscle |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.06.2020 | ||
| 500 | |a Date Revised 27.08.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 Wiley Periodicals, Inc. | ||
| 520 | |a It has been reported that asprosin is a novel adipokine which is augmented in mice and humans with type 2 diabetes (T2DM). Asprosin stimulates hepatic gluconeogenesis under fasting conditions. However, the roles of asprosin in inflammation, endoplasmic reticulum (ER) stress, and insulin resistance in skeletal muscle has not been studied. In the currents study, elevated levels of asprosin expression were observed in adipocytes under hyperlipidemic conditions. Treatment of C2C12 myocytes with asprosin-induced ER stress markers (phosphorylated inositol-requiring enzyme 1 and eukaryotic initiation factor 2, and CHOP expression) as well as inflammation markers (interleukin-6 expression, phosphorylated IκB, and nuclear translocated nuclear factor-κβ). Finally, asprosin treatment promoted exacerbation of insulin sensitivity as determined by levels of insulin receptor substrate 1 and Akt phosphorylation as well as glucose uptake. Moreover, treatment of asprosin augmented protein kinase C-δ (PKCδ) phosphorylation and nuclear translocation, but suppressed messenger RNA expression of sarcoplasmic reticulum Ca2+ ATPase 2b in both C2C12 myocytes and in mouse soleus skeletal muscle. These asprosin-induced effects were markedly decreased in small interfering (si) RNA-mediated PKCδ-knockdown in C2C12 myocytes. These results suggest that asprosin results in impairment of insulin sensitivity in skeletal muscle through PKCδ-associated ER stress/inflammation pathways and may be a valuable strategy for management of insulin resistance and T2DM | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ER stress | |
| 650 | 4 | |a asprosin | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a insulin resistance | |
| 650 | 4 | |a myocyte | |
| 650 | 7 | |a Fibrillin-1 |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a Peptide Hormones |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 650 | 7 | |a asprosin protein, mouse |2 NLM | |
| 650 | 7 | |a Protein Kinase C-delta |2 NLM | |
| 650 | 7 | |a EC 2.7.11.13 |2 NLM | |
| 650 | 7 | |a Sarcoplasmic Reticulum Calcium-Transporting ATPases |2 NLM | |
| 650 | 7 | |a EC 3.6.3.8 |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 700 | 1 | |a Kim, Hyoung-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Ho Ung |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Taekwang |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Jinwoo |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Uiseok |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Min Kyoon |e verfasserin |4 aut | |
| 700 | 1 | |a Jeong, Ji Hoon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cellular physiology |d 1965 |g 234(2019), 11 vom: 17. Nov., Seite 20888-20899 |w (DE-627)NLM000005304 |x 1097-4652 |7 nnns |
| 773 | 1 | 8 | |g volume:234 |g year:2019 |g number:11 |g day:17 |g month:11 |g pages:20888-20899 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jcp.28694 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 234 |j 2019 |e 11 |b 17 |c 11 |h 20888-20899 | ||